November 28, 2025

Celcuity Inc. (CELC) Stock Analysis: Unveiling a 3.19% Potential Upside Amidst Biotechnology Advances

Celcuity Inc. (NASDAQ: CELC) presents a compelling opportunity for investors keen on the biotechnology sector. As a clinical-stage biotech firm, Celcuity is dedicated to developing targeted therapies for solid tumors,..

InnovAge Holding Corp. (INNV) Stock Analysis: Navigating Challenges with 15.1% Revenue Growth

InnovAge Holding Corp. (NASDAQ: INNV), a key player in the healthcare sector, specifically within the medical care facilities industry, is making strides with its unique Program of All-Inclusive Care for..

SIGA Technologies Inc. (SIGA) Stock Analysis: Evaluating the Healthcare Innovator’s Strategic Position

SIGA Technologies Inc. (NASDAQ: SIGA), a pivotal player in the healthcare sector, specializes in the development and commercialization of pharmaceutical solutions focused on health security. Based in New York, the..

Relay Therapeutics, Inc. (RLAY) Stock Analysis: A Biotech Powerhouse with 73% Upside Potential

Relay Therapeutics, Inc. (RLAY), a clinical-stage precision medicines company, is making waves in the biotechnology sector with its innovative approach to drug discovery. Headquartered in Cambridge, Massachusetts, Relay Therapeutics is..

EyePoint Pharmaceuticals, Inc. (EYPT): Investor Outlook Reveals 140% Potential Upside in Retinal Biotech Pioneer

EyePoint Pharmaceuticals, Inc. (EYPT) is capturing the spotlight in the biotechnology sector with a staggering potential upside of 140.03%, according to recent analyst ratings. This U.S.-based company, with a market..

Verastem, Inc. (VSTM): Unlocking 50% Potential Upside in the Biotech Sector

For investors with a keen eye on the biotechnology sector, Verastem, Inc. (NASDAQ: VSTM) presents an intriguing opportunity. With a focus on developing breakthrough cancer therapies, Verastem’s innovative pipeline and..

PureTech Health plc (PRTC) Stock Analysis: Exploring the 542.70% Revenue Growth Potential

PureTech Health plc (PRTC), a biotechnology company listed in the United States, operates in the dynamic sector of healthcare, focusing on groundbreaking solutions that address unmet medical needs. With a..

MBX Biosciences, Inc. (MBX) Stock Analysis: Biotech Innovator with a 90% Upside Potential

MBX Biosciences, Inc. (MBX), a promising clinical-stage biopharmaceutical company, is making waves in the biotechnology sector with its innovative approach to developing precision peptide therapies for treating endocrine and metabolic..

Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Exploring a Potential 116.84% Upside in the Biotech Arena

Taysha Gene Therapies, Inc. (TSHA) is making waves in the biotechnology sector, capturing investor attention with a market cap of $1.33 billion and a potential upside of 116.84%. As a..

Cross Country Healthcare, Inc. (CCRN) Stock Analysis: Exploring a Potential 74% Upside in the Healthcare Sector

Cross Country Healthcare, Inc. (NASDAQ: CCRN) operates prominently within the healthcare sector, specifically in the medical care facilities industry. Based in Boca Raton, Florida, and established in 1986, the company..

MeiraGTx Holdings plc (MGTX) Stock Analysis: A Biotech Contender with a 235% Upside Potential

MeiraGTx Holdings plc (NASDAQ: MGTX), a clinical-stage genetic medicines company, is making waves in the biotech sector with a promising pipeline and substantial upside potential. With a market capitalization of..

Kamada Ltd. (KMDA) Stock Analysis: Exploring 116.91% Potential Upside in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA), headquartered in Rehovot, Israel, is a prominent player in the healthcare sector, specifically within the drug manufacturing industry focusing on specialty and generic pharmaceuticals. With a..

Opthea Limited (OPT) Stock Analysis: Navigating Biotech Volatility with a -70.67% Potential Downside

Opthea Limited (OPT), a Melbourne-based clinical-stage biopharmaceutical company, stands at a pivotal juncture within the biotechnology sector. Although its promising pipeline targets vascular endothelial growth factors (VEGF) and holds potential..

Upstream Bio, Inc. (UPB) Stock Analysis: Potential 70% Upside in Biotech Innovation

Investors seeking opportunities in the biotech sector might want to cast a keen eye on Upstream Bio, Inc. (NASDAQ: UPB), a company that’s making waves with its innovative approach to..

Treace Medical Concepts, Inc. (TMCI) Stock Analysis: Exploring an 81.73% Potential Upside in the Medical Device Sector

In the dynamic world of healthcare, Treace Medical Concepts, Inc. (NASDAQ: TMCI) stands out as a burgeoning player within the medical device industry. Although the company is currently navigating some..

Beta Bionics, Inc. (BBNX) Stock Analysis: Navigating Growth in the Promising Medical Device Sector

As the healthcare sector continues to innovate, Beta Bionics, Inc. (NASDAQ: BBNX) emerges as a compelling player within the medical devices industry, specifically targeting the diabetes management market. With a..

Eton Pharmaceuticals (ETON) Stock Analysis: Exploring an 85% Upside Potential in the Rare Disease Market

Eton Pharmaceuticals, Inc. (ETON), a key player in the healthcare sector, is making waves in the specialty and generic drug manufacturing industry with its ambitious focus on rare diseases. Headquartered..

Standard BioTools Inc. (LAB) Stock Analysis: Navigating a Healthcare Innovator with 8.39% Potential Upside

Standard BioTools Inc. (NASDAQ: LAB), a prominent player in the healthcare sector’s medical devices industry, offers a fascinating case study for investors seeking exposure to cutting-edge biotechnology tools. With a..

Akso Health Group (AHG) Stock Analysis: Exploring the Remarkable 415.8% Revenue Growth in China’s Healthcare Sector

For individual investors keeping a keen eye on the healthcare sector, Akso Health Group (NASDAQ: AHG) offers a compelling case study. This company, headquartered in Qingdao, China, operates within the..

Zymeworks Inc. (ZYME) Stock Analysis: A Promising Biotech with 27% Upside Potential

Zymeworks Inc. (NASDAQ: ZYME), a clinical-stage biotechnology firm, is capturing investor attention in the healthcare sector. With a market cap of $2.07 billion, the company is making significant strides in..

Search

Funds

November 28, 2025

Search

Funds

November 28, 2025

FTSE 100

Funds